Home > Boards > US OTC > Medical - Equipment > SiNtx Technologies, Inc. (AMDDW)

This is from the recent Prospectus, I have

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
KOmani Member Profile
 
Followed By 27
Posts 1,863
Boards Moderated 0
Alias Born 09/22/15
160x600 placeholder
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 6/3/2020 10:59:47 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2020 5:02:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/30/2020 4:32:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/30/2020 4:31:42 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/26/2020 6:07:49 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/23/2020 9:00:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/4/2020 7:01:02 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/2/2020 7:46:36 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2020 3:16:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/7/2020 5:22:03 PM
Registration of Additional Securities (up to 20%) (s-1mef) Edgar (US Regulatory) - 2/3/2020 4:40:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/30/2020 8:26:36 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 1/29/2020 8:02:31 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/21/2020 6:00:54 AM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 1/17/2020 5:02:46 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 1/17/2020 6:04:03 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 1/15/2020 2:03:59 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 1/10/2020 5:22:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/27/2019 4:30:50 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 12/27/2019 4:12:11 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 12/9/2019 4:07:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/18/2019 7:31:09 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 4:01:00 PM
KOmani   Saturday, 06/27/20 05:52:55 AM
Re: Luckypennyman post# 1
Post # of 21 
This is from the recent Prospectus, I have copied quite a bit because the bottom paragraph covers the repricing.

The issue at this point is why are the warrants trading this low?


May 2018 Public Offering Warrants



On May 14, 2018, we issued 11,370,000 common stock warrants (the “May 2018 Warrants”) in a public offering. The material terms and provisions of the May 2018 Warrants are summarized below. This summary of the May 2018 Warrants is not complete. For the complete terms of the May 2018 Warrants, you should refer to the form of May 2018 Warrant filed as an exhibit to the registration statement of which this prospectus forms a part.



Pursuant to a warrant agency agreement between us and American Stock Transfer & Trust Company, LLC, as warrant agent, the May 2018 Warrants were issued in book-entry form and are represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company, or DTC, and registered in the name of Cede & Co., a nominee of DTC, or as otherwise directed by DTC.



Exercisability, Exercise Price and Term. The May 2018 Warrants entitle the holder to purchase shares of our common stock at an exercise price equal to $0.48 per share. The May 2018 Warrants were exercisable immediately and expire on the five-year anniversary of the issuance date. The holder of a May 2018 Warrant will not be deemed a holder of our underlying common stock until the May 2018 Warrant is exercised, except as set forth in the May 2018 Warrants.



The exercise price and the number of shares issuable upon exercise of the May 2018 Warrants is subject to appropriate adjustment, similar to that described with respect to the Series B Preferred Stock above, in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock. Subject to certain exclusions contained in the May 2018 Warrant, the exercise price is also subject to adjustment in the event that we sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any common stock or common stock equivalents (as defined in the May 2018 Warrants), at an effective price per share less than the exercise price then in effect (including in the event we issued Series B Preferred Stock at a conversion price lower than the initial conversion price of the Series B Preferred Stock).

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist